Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

BackgroundInterleukin-13 receptor α 2 (IL13Rα2) is a promising tumor-directed antigen of malignant glioma (MG). Here, we examine the efficacy and safety of T cells containing a YYB-103 chimeric antigen receptor (CAR) that can preferentially bind to IL13Rα2 on MG cells.MethodsIL13 was modified on the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kiwan Kim, Ho-Shin Gwak, Nayoung Han, Eun Kyung Hong, Beom K. Choi, Sangeun Lee, Soyoung Choi, Ju-Hwang Park, Ji-Hye Seok, Yeongha Jeon, Hyuntae Cho, Song-Jae Lee, Yura Lee, Ki Taek Nam, Seong-Won Song
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	chimeric antigen receptor T cell immunohistochemistry interleukin-13 malignant glioma immunotherapy Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/dc3012fd96854bd3994a62b55e0a09fb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

Ejemplares similares